HHCP
RVMD icon

Hilton Head Capital Partners’s Revolution Medicines RVMD Stock Holding History

Hilton Head Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5K Hold
83
– – 0.01% 519
2026
Q1 		$8.07K Sell
83
-110
-57% -$11.1K ﹤0.01% 616
2025
Q4 		$15.4K Buy
+193
New +$12.7K 0.01% 521

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Hilton Head Capital Partners's RVMD Position: Q2 2026 in Review

Hilton Head Capital Partners held its Revolution Medicines (RVMD) position steady in Q2 2026 at 83 shares worth $15.5K. The position accounts for 0.01% of the portfolio, ranked #519.

Hilton Head Capital Partners first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Hilton Head Capital Partners held 83 shares of Revolution Medicines worth $15.5K as of Q2 2026.
  • Hilton Head Capital Partners left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #519 holding.
  • Hilton Head Capital Partners first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.